A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.
about
Intelligent design: combination therapy with oncolytic virusesThe status of gene therapy for brain tumorsCurrent developments in adenovirus-based cancer gene therapyAnti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical AppraisalTargeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinomaCombined bacterial and viral treatment: a novel anticancer strategyOverview of current immunotherapeutic strategies for gliomaOncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsFrom scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancerOncolytic Sendai virus-based virotherapy for cancer: recent advancesAdenovirus vectors for gene therapy, vaccination and cancer gene therapyOncolytic virus therapy for glioblastoma multiforme: concepts and candidatesOncolytic viral therapy for pancreatic cancer: current research and future directionsVirotherapy: cancer gene therapy at last?Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpointsA dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibitionImmunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapyEfficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coliCyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.Targeting tumor suppressor networks for cancer therapeutics.Virotherapy against malignant glioma stem cellsA novel oncolytic adenovirus based on simian adenovirus serotype 24Current issues and future directions of oncolytic adenoviruses.Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cellsCancer targeted therapeutics: From molecules to drug delivery vehicles.Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesReplicative adenoviruses for cancer therapy.p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effectAdenoviral vector-mediated gene therapy for gliomas: coming of age.Artificial riboswitches for gene expression and replication control of DNA and RNA viruses.Oncolytic viruses: From bench to bedside with a focus on safety.Anatomical differences determine distribution of adenovirus after convection-enhanced delivery to the rat brain.Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing.Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas.Experimental approaches for the treatment of malignant gliomas.Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cellsTreatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
P2860
Q24628227-A969CE0D-18BC-4979-B523-97980BEDEF3BQ24651009-8783097B-24B2-4983-8B69-1DC788456AB8Q24683229-8D8FBC1E-9192-4400-9617-A25F7E073A3AQ26744536-F4D3D820-A737-441F-ADCD-185704ED6135Q26772315-DFD08E16-D45A-47D5-B2D1-C88172A6E0BBQ26773180-5E235F00-6B35-48AA-AD55-CF70C3454286Q26776345-053F341D-A4C8-46AE-830D-CBEFFA7107E3Q26776553-1372A992-C144-4220-B48A-9900324DACBEQ26822694-E02612D8-1C54-4D5B-BC56-78FD30AD7CAFQ26825239-9B521113-E45E-4F7D-9B0E-0A4D69C7A2B0Q27001601-1CCCA233-0D01-417D-BB24-0CBFB8E4904AQ27007519-8EF9F9A7-316E-4749-B968-71C62BFB3D2FQ27011439-1EE5D0BC-3FB5-4BFC-832E-95FE37E59C38Q28066228-DC0489DE-0A09-4B37-9992-E78B4EC3B0B1Q28083515-30CAB931-A5BE-403F-AA23-5E571188FC4EQ28477181-264D5315-FD4B-4BF5-BB6C-9CC1B5376C4EQ30899557-6099567F-5456-4A13-8AB6-861D18B87834Q33252754-681AD082-373E-4469-B1FE-39014C0A0F87Q33641230-CCFA41D0-6F4C-42E7-87E1-E3FA5E5458E5Q33657519-1BFF4FD7-DDE6-4479-A525-DC9BE4ACE387Q33665530-6B7D7F68-8424-49BF-BE15-E7D0AFF66643Q33688856-BA872500-5294-4A4B-B1CA-4AFF5532A5DEQ33730705-ABC76404-A5D2-44BD-B3C3-A7D4F8C51483Q33747762-46EA07F0-9646-4A25-B02C-54BB9397B1EFQ33862517-36E5D6C1-5FAC-4E3F-A3AE-16B8F0D1465BQ33887986-AF51467E-023D-4D32-936C-BCF72272AC62Q33924550-99320C03-6CFF-4F03-93B4-F4AE9E42CB65Q33963944-6FA65928-43E0-4DA0-9604-C8516FA74D6DQ33997928-791FD7A6-F4DE-469C-B3EC-D7C45AFFD402Q34008026-EBD02938-3071-43D2-9215-9223798B87E2Q34022048-2D4AE1D3-1B99-48F9-8A91-8F704FBC0B5CQ34039619-0FB59872-FC00-4821-8F2F-1585BD606554Q34044071-7CA188AE-98BF-4C44-87F8-E8406A06EE58Q34055421-C6AFD765-FE0F-4B4F-807C-F7CCEF7B2521Q34058399-7909D3FD-8315-4347-95F9-A36A47F5028AQ34102273-B5260D45-6836-47BE-A42E-CEC628B8BEE2Q34109937-CD797AAB-5508-41FF-B4CF-E3942A2738E8Q34127138-C073CD0B-796F-40F2-8297-728E98438A62Q34154904-4BD2E464-4BEF-42CF-886B-4F9AD141CBA9Q34183436-C513D603-1C94-46C5-9B35-0C1B0C5A9DF8
P2860
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
A mutant oncolytic adenovirus ...... es anti-glioma effect in vivo.
@en
A mutant oncolytic adenovirus ...... es anti-glioma effect in vivo.
@nl
type
label
A mutant oncolytic adenovirus ...... es anti-glioma effect in vivo.
@en
A mutant oncolytic adenovirus ...... es anti-glioma effect in vivo.
@nl
prefLabel
A mutant oncolytic adenovirus ...... es anti-glioma effect in vivo.
@en
A mutant oncolytic adenovirus ...... es anti-glioma effect in vivo.
@nl
P2093
P356
P1433
P1476
A mutant oncolytic adenovirus ...... es anti-glioma effect in vivo.
@en
P2093
Gomez-Manzano C
Kyritsis AP
McDonnell TJ
Mitlianga P
P2888
P356
10.1038/SJ.ONC.1203251
P407
P577
2000-01-01T00:00:00Z